SRPT

Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health

Retrieved on: 
Venerdì, Maggio 3, 2024
Health, Neurology, Genetics, Research, Science, Pharmaceutical, Biotechnology, Neuromuscular disease, SRPT, National academy, DSM-IV codes, Hospital, Muscular dystrophy, Book, SMA, Cell, Duchenne, Disease, TIME, Patient, Sarepta Therapeutics, Gene, Society, Nationwide, Duchenne muscular dystrophy, Head, Therapy, Global health, Pharmaceutical industry

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year.
  • The TIME100 Health list recognizes the impact, innovation, and achievement of the world’s most influential individuals in health.
  • In addition to recognition on the TIME100 Health list, Dr. Mendell is a 2024 recipient of the King Faisal Prize Laureate in Medicine.
  • He is also a published author of more than 400 peer-reviewed articles and books about skeletal muscle disease, peripheral nerve disorders and gene therapy.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Martedì, Aprile 30, 2024
Health, FDA, Genetics, Other Science, Research, Science, Pharmaceutical, SRPT, Compensated emancipation, Therapy, Employment

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 30, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in April 2024.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 30, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in April 2024.
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 0 shares of Sarepta's common stock, and in the aggregate 17,090 restricted stock units (“RSUs”).
  • The options have an exercise price of $126.66 per share, which is equal to the closing price of Sarepta's common stock on April 30, 2024 (the “Grant Date”).

Sarepta Therapeutics to Announce First Quarter 2024 Financial Results

Retrieved on: 
Mercoledì, Aprile 24, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, SRPT, Therapy, PIN, Interest

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024.
  • Subsequently, at 4:30 p.m.
  • E.T., the Company will host a conference call to discuss its first quarter 2024 financial results.
  • Interested parties participating by phone will need to register using this online form .

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Venerdì, Marzo 29, 2024
Biotechnology, Infectious Diseases, Health, Genetics, Pharmaceutical, Employment, Compensated emancipation, SRPT, Therapy

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in March 2024.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in March 2024.
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 5,100 shares of Sarepta's common stock, and in the aggregate 9,335 restricted stock units (“RSUs”).
  • The options have an exercise price of $129.46 per share, which is equal to the closing price of Sarepta's common stock on March 29, 2024 (the “Grant Date”).

Sarepta Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
Lunedì, Marzo 4, 2024
Health, FDA, Genetics, Research, Science, Pharmaceutical, Biotechnology, SRPT, Therapy, Fontainebleau Miami Beach, Software, Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming investor conferences:

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming investor conferences:
    Leerink Partners Global Biopharma Conference on Mon., March 11, 2024, at 10:00 a.m. E.T at the Fontainebleau Hotel in Miami, Fla.
    Barclays 26th Annual Global Healthcare Conference on Tue., March 12, 2024, at 3:05 p.m. E.T.
  • at the Loews Miami Beach Hotel in Miami, Fla.
  • The presentations will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days.
  • Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program

Retrieved on: 
Giovedì, Febbraio 29, 2024
University, Education, Health, Philanthropy, General Health, Hispanic, Training, Genetics, Foundation, Consumer, Continuing, SRPT, Duchenne, Duchenne muscular dystrophy, Therapy, Student, PDT, Diagnosis, Sibling, Nursing

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year.
  • “Sarepta is proud to announce the opening of Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year.
  • Only applicants diagnosed with Duchenne or applicants who have a sibling diagnosed with Duchenne are eligible for the program.
  • Previous recipients of Route 79 scholarships may apply for the 2024 Scholarship Program, however, applicants may only receive a Route 79 scholarship up to four times.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Giovedì, Febbraio 29, 2024
FDA, Health, Research, Pharmaceutical, Science, Biotechnology, SRPT, Compensated emancipation, Therapy, Employment

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Feb. 29, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 5 individuals hired by Sarepta in February 2024.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Feb. 29, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 5 individuals hired by Sarepta in February 2024.
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 0 shares of Sarepta's common stock, and in the aggregate 6,300 restricted stock units (“RSUs”).
  • The options have an exercise price of $127.90 per share, which is equal to the closing price of Sarepta's common stock on Feb. 29, 2024 (the “Grant Date”).

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Mercoledì, Febbraio 28, 2024
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, SRPT, Hart–Scott–Rodino Antitrust Improvements Act, Investment, Interest, Sarepta Therapeutics, Part, Sale, University, Trial of the century, Ageing, BLA, GAAP, Therapy, BioMarin Pharmaceutical, Income tax, PMR, Depreciation, Magnesium deficiency, Nationwide Children's Hospital, Hospital, Safety, Patent, Clinical trial, Biologics license application, Mutation, Priority review, Acquisition, PIN, Dystrophin, FDA, Food, DMD, Duchenne muscular dystrophy, U.S. FDA, Agency, Patient, PRV, PMO, Pharmaceutical industry

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2023.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2023.
  • Beginning in the fourth quarter of 2023, amortization of in-licensed rights (formerly included within depreciation and amortization expense) and income tax (benefit) expense are no longer excluded from the non-GAAP results.
  • Non-GAAP financial results for the fourth quarter and full-year 2022 have been updated to reflect this change for comparability.
  • All relevant non-GAAP measures are reconciled from their respective GAAP measures in the attached table “Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures.”

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Mercoledì, Febbraio 21, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Other Health, Interest, SRPT, Therapy, PIN

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2023 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 28, 2024.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2023 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 28, 2024.
  • Subsequently, at 4:30 p.m.
  • E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2023 financial results and to provide a corporate update.
  • Interested parties participating by phone will need to register using this online form .

Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication

Retrieved on: 
Venerdì, Febbraio 16, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Infectious Diseases, Genetics, SRPT, Roche, Physician, Food, Sarepta Therapeutics, DMD, Duchenne muscular dystrophy, BLA, Agency, Therapy, Priority review, Patient, Disease, Biologics license application, Efficacy, Mutation, Pharmaceutical industry

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted and filed the Company's efficacy supplement to the Biologics License Application (BLA) for ELEVIDYS (delandistrogene moxeparvovec-rokl) (the “Efficacy Supplement”).

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted and filed the Company's efficacy supplement to the Biologics License Application (BLA) for ELEVIDYS (delandistrogene moxeparvovec-rokl) (the “Efficacy Supplement”).
  • The goals of the Efficacy Supplement are twofold:
    To expand the labeled indication for ELEVIDYS as follows: “[ELEVIDYS is indicated for] the treatment of Duchenne muscular dystrophy (DMD) patients with a confirmed mutation in the DMD gene.”
    To convert the ELEVIDYS accelerated approval to a traditional approval.
  • The FDA has granted the Efficacy Supplement a Priority Review with a review goal date of June 21, 2024.
  • The Agency has also confirmed they are not planning to hold an advisory committee meeting to discuss the supplement.